title: Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate.
abstract: The objective of the present study was to incorporate the hydrophilic drug diminazenediaceturate at a high loading into lipid nanoparticles by creating nanoparticles from lipid-drug conjugates (LDC). IR and DSC data showed that the antitrypanosomal drug diminazene is able to react with fatty acids to form water-insoluble salts like diminazenedistearate and -dioleate. The salts could be transformed into nanoparticles using high-pressure homogenization technique, established for solid lipid nanoparticles (SLN). By using polysorbate 80 as surfactant, physically stable LDC nanoparticle dispersions of both salts could be obtained. The mean PCS diameters and polydispersity indices were 364 nm and 0.233 for diminazenedistearate and 442 nm and 0.268 for diminazenedioleate, respectively. Due to the composition of the LDC bulk materials, nanoparticles with a high drug load of 33% (w/w) were obtained even for this highly water-soluble drug diminazenediaceturate. The new carrier system of LDC nanoparticles overcomes one limitation of SLN, i.e. the limited loading capacity for hydrophilic drugs. Transforming water-soluble hydrophilic drugs into LDC and formation of nanoparticles allows prolonged drug release and targeting to specific sites by i.v. injection. These results provide a first basis of using LDC-polysorbate 80 nanoparticles for brain delivery of diminazene to treat second stage human African trypanosomiasis (HAT).
authors.affiliation: Department of Pharmaceutics, Biopharmaceutics and Biotechnology, The Free University of Berlin, Germany.
authors.forename: Carsten
authors.initials: C
authors.lastname: Olbrich
authors.forename: Andrea
authors.initials: A
authors.lastname: Gessner
authors.forename: Oliver
authors.initials: O
authors.lastname: Kayser
authors.forename: Rainer Helmut
authors.initials: RH
authors.lastname: Müller
mesh_terms: D001812:Blood-Brain Barrier; D004133:Diminazene / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry*; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods*; D004355:Drug Stability; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008863:Microspheres; D036103:Nanotechnology; D010316:Particle Size; D017550:Spectroscopy, Fourier Transform Infrared; D013501:Surface-Active Agents; D014344:Trypanocidal Agents / Q000008:administration & dosage / Q000737:chemistry*; D014353:Trypanosomiasis, African / Q000378:metabolism
chemical_list: D004337:Drug Carriers; D008055:Lipids; D013501:Surface-Active Agents; D014344:Trypanocidal Agents; C003915:diminazene aceturate; D004133:Diminazene